Overview of Сакур

What Type of Medicine is Сакур (Lacidipine)?

Сакур is an oral, single-ingredient antihypertensive agent used for the management of high blood pressure, classified as a highly selective Calcium Channel Blocker (CCB). Its active component is Lacidipine, a synthetic small molecule that belongs specifically to the dihydropyridine group of calcium antagonists. In terms of pharmacological classification, its action is primarily targeted at the circulatory system, focusing on the blood vessels. Lacidipine is used for its therapeutic efficacy in reducing blood pressure while minimizing direct cardiac effects. The medicine is clinically utilized for providing effective control of elevated blood pressure, which is a key necessity in managing essential hypertension in adult patients.

Composition and Physical Form of Сакур

The efficacy of Сакур stems from its sole active ingredient, Lacidipine, which is presented as an oral, film-coated tablet. This synthetic small molecule is incorporated into a formulation designed for once-daily use. The film-coated tablet structure ensures the stability and precise delivery of the active substance. A characteristic of Lacidipine is its high lipophilicity (fat solubility), a feature important for achieving sustained action in the body, which allows for consistent 24-hour therapeutic coverage with a single daily dose.

General Purpose and Action of this Calcium Channel Blocker

The overarching purpose of Сакур is to achieve a controlled and sustained reduction in high blood pressure (hypertension). This is accomplished because Lacidipine promotes the relaxation and widening (vasodilation) of the peripheral blood vessels by inhibiting the movement of calcium ions into the vascular muscle cells. By making the blood vessels wider and less constricted, the medication lowers the overall resistance to blood flow, which in turn reduces the physical workload on the heart and helps normalize systemic blood pressure. This class of calcium channel blockers is specifically designed to relax blood vessels to lower blood pressure.

What side effects are possible with Сакур?

Possible Side Effects and Safety Information

The safety profile of Lacidipine (Сакур) describes potential adverse effects based on official regulatory classifications, generally organized by the physiological system affected and the frequency of occurrence. Effects are often linked to the medicine's primary action of widening blood vessels (vasodilation).

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to the following regulatory frequency standards:

Classification	Frequency (Examples)
Common	Headache, Dizziness, Flushing, Oedema (swelling), Palpitations, Nausea, Asthenia (weakness), Rash.
Uncommon	Hypotension (low blood pressure), Aggravation of underlying angina pectoris, Syncope (fainting), Gingival hyperplasia.
Rare	Angioedema (serious swelling), Urticaria (hives).
Very Rare	Depression, Tremor.

Serious Adverse Reactions and Constraints

Official labeling highlights the potential for aggravation of underlying angina pectoris, which is noted to be more likely at the start of treatment, and rare but serious reactions like Angioedema. The medicine is contraindicated in patients with pre-existing conditions such as aortic stenosis and cardiogenic shock.

Population-Specific Safety Notes

Particular caution is advised for patients with hepatic impairment, as the body's exposure to the medicine may be increased. Use in pregnancy is generally advised only when the potential benefit outweighs the risk, considering the documented possibility of relaxation of the uterine muscle at term. Patients who experience dizziness are cautioned regarding activities requiring concentration, such as driving.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Сакур (Lacidipine) is defined by the official prescribing information as a medical emergency primarily associated with the consequences of excessive peripheral vasodilation, which leads to pronounced and potentially life-threatening cardiovascular instability.

Aspect	Official Regulatory Statement
Documented Manifestations	Overdose is typically defined by profound and prolonged systemic hypotension due to excessive peripheral vasodilation. Changes in heart rate, such as tachycardia (fast heart rate) or the potential for bradycardia (slow heart rate), are also documented.
Severe Outcomes	The risk of shock or unconsciousness is officially recognized as a serious consequence of marked and sustained low blood pressure resulting from overdosage.
Required Emergency Action	Regulatory guidance strictly mandates that individuals seek immediate medical attention or go to a hospital straight away when an overdose is suspected. The patient should take the medicine packaging.
Treatment Principle	No specific antidote is known for Lacidipine overdose. Management is therefore limited to symptomatic and supportive treatment and must include close observation of cardiac function and vital signs.

This profile confirms that any suspected over-ingestion represents a medical emergency requiring professional intervention to manage the severe drop in blood pressure and to monitor vital functions effectively.

Therapeutic Uses of Сакур

The treatment is relevant for easing symptoms related to systemic imbalance, and is commonly used for the chronic management of essential hypertension (high blood pressure) in adults. The medication is applied across domains where long-term supportive management of elevated pressure is considered appropriate. The main indication for use is the treatment of hypertension, which may be managed alone or in combination with other agents.

This medication is used for managing symptoms related to heightened physiological activity, specifically addressing abnormally high pressure readings. It helps address the core condition involving episodic or fluctuating manifestations of high blood pressure.

The medication is commonly used across therapeutic domains that include the chronic treatment of essential hypertension, management of high pressure in patient groups such as the elderly and those with Type 2 diabetes, and addressing specific patterns like isolated systolic hypertension.

“By maintaining stability in blood pressure, the treatment contributes to easing the overall symptom load for patients during chronic management.”

The supportive role of Lacidipine may assist with maintaining functional stability over time and contributes to easing the overall strain on the cardiovascular system.

Quick Fact: Supportive Management for Systemic Pressure Fluctuations

The medication may assist with symptoms related to systemic imbalance by contributing to consistent, 24-hour management of high pressure, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Сакур? - Official Regulatory Information

The eligibility for using Сакур (Lacidipine) is strictly defined by official regulatory bodies based on population characteristics and pre-existing medical conditions.

Populations for Whom Use is Prohibited or Restricted

Classification	Population/Condition
Contraindicated (Must Not Use)	Severe aortic stenosis or a myocardial infarction (heart attack) within the last month.
Contraindicated	Known hypersensitivity to lacidipine or to any other dihydropyridine calcium channel blocker.
Not Recommended	Children and adolescents under 18 years old, as safety and efficacy data are not established.
Caution/Conditional Use	Patients with impaired liver function or poor cardiac reserve.
Conditional Use	Pregnancy and Lactation: Use is only permitted when the official benefit for the mother outweighs the potential risk to the fetus or neonate.

Established Use

Сакур is established for use in adult patients for the treatment of essential hypertension. Older adults may generally use the medicine without requiring a specific initial dose adjustment. Furthermore, use is generally allowed for patients with renal impairment, as specific dose adjustments are typically not required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lacidipine (Сакур) is subject to several documented interaction patterns that are formally established in regulatory prescribing information. The clearance of lacidipine from the body involves the cytochrome P450 enzyme CYP3A4, which is the basis for several drug-drug interactions.

Drug-Drug Interactions

Exposure-Altering Metabolic Interactions: Co-administration with strong CYP3A4 inhibitors, such as Itraconazole or Cimetidine, may increase the plasma level of lacidipine. Conversely, strong CYP3A4 inducers, such as Rifampicin, may interfere with the metabolism and elimination process. Concomitant use with corticoids or Tetracosactide might decrease the antihypertensive effect of lacidipine.
Pharmacodynamic Interactions: Combining lacidipine with other antihypertensive agents (e.g., diuretics, beta-blockers) can result in an additive hypotensive effect. Regulatory documents note that no specific interaction problems have been identified with agents like Digoxin, Tolbutamide, or Warfarin.

Food and Substance Interactions

Grapefruit Juice: Lacidipine should not be taken with grapefruit juice because its bioavailability may be altered.
Alcohol: Consumption of alcohol is noted with caution as it may increase the hypotensive effects of lacidipine.

Population-Specific Interaction Notes

Impaired Liver Function: Use requires caution in patients with impaired liver function, as the antihypertensive effect may be increased in this population due to enhanced bioavailability.

Mechanism of Action

Selective Blockade of Vascular Calcium Channels

The primary mechanism involves acting as an antagonist against the voltage-dependent L-type Calcium Channels (Cav1.2) found on the membranes of vascular smooth muscle cells (VSMCs). This molecular blockade prevents the influx of extracellular calcium ions (Ca^2+), which are signaling molecules required for the excitation-contraction coupling pathway to initiate muscle shortening.

Reducing Peripheral Vascular Resistance

By inhibiting the calcium-driven contraction of the smooth muscle, the drug promotes sustained vasodilation (widening) of the peripheral arterioles. This physiological change reduces the opposition to blood flow, leading directly to a decrease in the Total Peripheral Vascular Resistance (PVR). The reduction in resistance is the core systemic adjustment resulting from the drug's mechanism of action.

Sustained Action via Membrane Partitioning

The high lipophilicity of Lacidipine allows the molecule to embed within the lipid bilayer of the blood vessel membranes, creating a local reservoir. This sustained binding and slow release kinetic is the direct mechanism responsible for maintaining effective calcium channel blockade over a full 24-hour period, contributing to continuous modulation of vascular tone.

Dosage and Administration Information

Administration Guidelines for Lacidipine

The usage of Сакур, which contains the active substance Lacidipine, follows a structured protocol centered on oral administration for the chronic management of its approved indication. Instructions for dose and scheduling are established to ensure consistent therapeutic application.

Administration Protocol

The medicine is formulated as an oral, film-coated tablet and must be swallowed whole with a drink of water; it should not be crushed or chewed. It is taken once daily, preferably in the morning, and adherence to taking the dose at the same time each day is required to maintain consistent therapeutic levels. The tablet can be administered with or without food. A key constraint on proper use is the mandate to avoid grapefruit juice as it can alter the systemic exposure of the medication.

Dosing and Adjustment

The typical starting dose for adults is 2 mg once daily. The usual maintenance range is between 2 mg and 6 mg, with a maximum recommended dose of 6 mg per day. Any increase in dose should only be considered after an adequate period, typically no less than 3 to 4 weeks, to allow the full pharmacological effect of the current dose to be assessed before titration. If a dose is missed, the next scheduled dose should be taken at the usual time; a double dose should not be taken to compensate.

Usage in Specific Groups

Dosing recommendations indicate that no dose adjustment is typically required for older adults or in cases of mild to moderate renal or hepatic impairment. However, use of Lacidipine is not established nor recommended for the pediatric population (individuals under 18 years of age) due to a lack of sufficient clinical data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Сакур (Lacidipine)

Evidence for Use in Managing Essential High Blood Pressure

Lacidipine was studied in research contexts involving essential high blood pressure in various Randomized Controlled Trials (RCTs). This rigorous research examined patterns of change in both Systolic and Diastolic Blood Pressure in adult patients diagnosed with mild to moderate high blood pressure. Studies monitored populations over several years and tracked the occurrence of major health events, such as stroke or heart attack, in addition to changes in blood pressure levels.

It is important to understand that trials were often not designed to establish superiority in preventing every major long-term health outcome compared to all other established therapies. Furthermore, data for certain groups remain insufficient, specifically patients with severe, uncontrolled hypertension or those with significant kidney or liver disease, who were often not included in the primary clinical trials.

Evidence in Specific Adult Patient Groups and Hypertension Patterns

Studies explored patterns related to blood pressure in specific populations. Long-term randomized trials included older adults to monitor how outcomes were observed, examining patterns related to isolated systolic hypertension management. Research also examined the medicine in adults with high blood pressure who also have Type 2 diabetes mellitus. Results from these trials apply only to the populations studied and contribute to the broader evidence landscape for treating hypertension in special groups.

Research on Vascular Structure and Surrogate Endpoints

Beyond monitoring blood pressure, specific research explored patterns related to changes in the structure of blood vessels. One notable long-term study (ELSA) focused on a surrogate endpoint: the measurement of Carotid Intima-Media Thickness (IMT), a physical measurement used to gauge vascular changes. Findings described patterns observed in the measured IMT over the study period. However, since IMT is a surrogate, research provides context but does not determine whether that change translates to a definitive reduction in major events like strokes or heart attacks. The comparative evidence is lacking for hard clinical outcomes against a full range of alternative treatments.

Key Studies & References

Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients.

Frequently Asked Questions (FAQ)

Common questions about Сакур (FAQ)

Q: How quickly should I expect to see an effect from Сакур?

A: Regulatory pharmacokinetic data indicates that the onset of action for this medicine is generally observed between 30 and 50 minutes after taking the tablet. The full therapeutic effect is typically established over time as the once-daily administration aims to maintain consistent levels.

Q: If I miss a dose of Сакур, what generally happens?

A: Official administration guidelines strictly instruct users not to take a double dose to compensate for a missed one. As the medicine is intended for once-daily use to maintain consistent blood pressure control, missing a dose may affect the continuity of the intended 24-hour therapeutic coverage.

Q: Are there common side effects that usually go away?

A: Official product information describes that some commonly reported effects are often transient, meaning they may lessen or disappear with continued use of the medicine at the same dosage. These effects can include headache, dizziness, flushing, palpitations, and swelling of the ankles.

Q: Are there different rules for women who are pregnant or breastfeeding?

A: There are currently no available data on the safety of the medicine when used during human pregnancy. Official guidance indicates that its use is generally considered only when the potential benefit for the patient is judged to outweigh the potential risk. No specific data or rules regarding the use of the medicine during the lactation (breastfeeding) period are provided in the official documentation.

Q: Does Сакур affect your liver or kidneys?

A: Regulatory documents note that the medicine is primarily eliminated by the liver, and caution is advised for patients with existing impaired liver function. Regarding the kidneys, the dose typically does not require adjustment for kidney disease, as the medicine is not primarily cleared through this route.

Q: Can I drive a car while taking Сакур?

A: Official labeling advises that patients who experience side effects such as dizziness or related symptoms should be cautious about driving or operating machinery. Patients who experience such symptoms are cautioned regarding undertaking these activities, as they may affect concentration and ability.

Q: How does Сакур compare to similar over-the-counter medicines?

A: The medicine is officially classified as a Calcium Channel Blocker and is indicated for the management of high blood pressure. This class of medicine is only available as a prescription-only treatment and is not classified as an over-the-counter medicine.

Q: What is the difference between Сакур and a generic version?

A: Regulatory bodies require that the generic version of the medicine contain the identical active ingredient (Lacidipine) as the brand-name product. It must also meet strict standards for bioequivalence, meaning it is absorbed by the body at the same rate and to the same extent. While the active component is the same, the inactive ingredients may differ.

Q: What is the general success rate mentioned in studies for Сакур?

A: Clinical studies have examined the medicine’s ability to lower both systolic and diastolic blood pressure, observing patterns of reduction in the populations studied. However, research trials were often not designed to compare one single 'success rate' figure against all other established therapies.

Q: Does the time of day matter when taking Сакур?

A: Official guidelines state the medicine is taken once daily, preferably in the morning, to help maintain consistent therapeutic levels over a 24-hour period. This consistent timing helps ensure continuous blood pressure modulation.

Q: Are allergic reactions to Сакур common?

A: Serious allergic reactions, such as rapid swelling of the face, mouth, and throat (angioedema), have been reported in the rare frequency category, affecting up to 1 in 1,000 people. A known hypersensitivity to the drug is a condition where its use is contraindicated.

Q: Does Сакур change the way other medicines are absorbed?

A: Official documentation on drug interactions focuses primarily on how the medicine is metabolized by a specific liver enzyme (CYP3A4). This metabolism may alter the plasma levels of co-administered medicines that share this same pathway. Changes to the absorption of other medicines are not highlighted as a primary mechanism of interaction.

Q: Is the research on Сакур new or has it been studied for many years?

A: The medicine has been the subject of long-term randomized controlled trials and has been clinically recognized for many years. It has an established history following its original development and subsequent regulatory approval.

Q: Is Сакур a sedative?

A: Sedation is not listed as a side effect in the official regulatory documentation. However, common side effects can include dizziness and asthenia (a feeling of general weakness), which may indirectly affect alertness and concentration.

Q: What are the known limitations of Сакур's treatment success?

A: Official documents state that the safety and efficacy of the medicine in the treatment of malignant hypertension has not been established. Furthermore, it is not considered useful for the secondary prevention of myocardial infarction (heart attack).

Q: What is the process for reporting a side effect for Сакур?

A: The process for reporting side effects, known as pharmacovigilance, is managed by national regulatory agencies. Patients are encouraged to communicate any suspected adverse reactions to their prescribing doctor or pharmacist. Detailed information on how to report directly to the national authority is generally provided in the patient information leaflet.

Q: If I have a chronic illness, is Сакур still an option?

A: The medicine is contraindicated in certain severe pre-existing heart conditions, such as severe aortic stenosis or a heart attack within the last month. Use also requires specific caution in patients who have impaired liver function or poor cardiac reserve. Eligibility is determined based on official regulatory constraints.

Q: What should I do if my condition doesn't seem to improve after starting Сакур?

A: The official administration protocol describes a minimum assessment period of 3 to 4 weeks to allow for the full pharmacological effect to be established before any dose modification is considered. This period is required before deciding on further dosage changes.

How should Сакур be stored and disposed of?

Storage and Disposal Requirements for Lacidipine (Сакур)

The storage and disposal of Lacidipine tablets must strictly adhere to regulatory mandates to maintain product stability and safety.

Required Storage Conditions

The medicine is stable at standard room temperature and does not require special temperature control. The most critical requirement is that the tablets must be protected from light and humidity.

Storage Rule	Requirement
Container	Store in the original package
Light/Moisture	Mandatory protection from light
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Disposal of any unused or expired product must be carried out in accordance with local requirements established by regional regulatory bodies. The product is not classified as hazardous and requires no special handling procedures for waste material.

Сакур